P-glycoprotein: A defense mechanism limiting oral bioavailability and CNS accumulation of drugs

International Journal of Clinical Pharmacology and Therapeutics

Volumn 38, Issue 2, 2000, Pages 69-74

  Fromm, M F ^a  

^a DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

Author keywords

Bioavailability; Blood brain barrier; Drug transport; P glycoprotein

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CELIPROLOL; CYCLOSPORIN; DIGOXIN; DRUG METABOLIZING ENZYME; ERYTHROMYCIN; GLYCOPROTEIN P; INDINAVIR; LOPERAMIDE; NELFINAVIR; PACLITAXEL; PROTEINASE INHIBITOR; QUINIDINE; RIFAMPICIN; RITONAVIR; SAQUINAVIR;

ARTICLE; BLOOD BRAIN BARRIER; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG CROSS REACTIVITY; DRUG DISPOSITION; DRUG ELIMINATION; DRUG TRANSPORT; ENDOTHELIUM CELL; KNOCKOUT MOUSE; MULTIDRUG RESISTANCE; ORAL DRUG ADMINISTRATION; PROTEIN EXPRESSION; TUMOR CELL;

EID: 0033980182     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP38069     Document Type: Article

References (44)

1. Alsenz J, Steffen H, Alex R 1998 Active apical secretory efflux of the HIV protease inhibitors saquinavir and ritonavir in Coco-2 cell monolayers. Pharm Res 15: 423-428
2. Angelin B, Arvidsson A, Dahlqvist R, Hedman A, Schenck-Gustafsson K 1987 Quinidine reduces biliary clearance of digoxin in man. Eur J Clin Invest 17: 262-265
3. Cavet ME, West M, Simmons NL 1996 Transport and epithelial secretion of the cardiac glycoside, digoxin, by human intestinal epithelial (Caco-2) cells. Br J Pharmacol 118: 1389-1396
4. Cordon-Cardo C, O'Brien JP, Boccia J, Casals D, Bertino JR, Melamed MR 1990 Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem 38: 1277-1287
5. de Lannoy IA, Koren G, Klein J, Charuk J, Silverman M 1992a Cyclosporin and quinidine inhibition of renal digoxin excretion: evidence for luminal secretion of digoxin. Am J Physiol 263: F613-22
6. de Lannoy IA, Silverman M 1992b The MDR1 gene product, P-glycoprotein, mediates the transport of the cardiac glycoside, digoxin. Biochem Biophys Res Commun 189: 551-557
7. de Waziers I, Cugnenc PH, Yang CS, Leroux JP, Beaune PH 1990 Cytochrome P450 isoenzymes, epoxide hydrolase and glutathione transferases in rat and human hepatic and extrahepatic tissues. J Pharmacol Exp Ther 253: 387-394
8. Doering W, König E 1978 Anstieg der Digoxinkonzentration im Serum unter Chinidinmedikation. Med Klin 73: 1085-1088
9. Fromm MF, Busse D, Kroemer HK, Eichelbaum M 1996 Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin. Hepatology 24: 796-801
10. Fromm MF, Dilger K, Busse D, Kroemer HK, Eichelhaum M, Klotz U 1998 Gut wall metabolism of verapamil in older people: effects of rifampicin-mediated enzyme induction. Br J Clin Pharmacol 45: 247-255
11. Fromm MF, Kim RB, Stein CM, Wilkinson GR, Roden DM 1999 Inhibition of P-glycoprotein-mediated drug transport: a unifying mechanism to explain the interaction between digoxin and quinidine. Circulation 99: 552-557
12. Germann UA 1996 P-glycoprotein - a mediator of multidrug resistance in tumour cells. Eur J Cancer 32A: 927-944
13. Gramatte T, Oertel R 1999 Intestinal secretion of intravenous talinolol is inhibited by luminal R-verapamil. Clin Pharmacol Ther 66: 239-245
14. Gramatté-T, Oertel R, Terhaag B, Kirch W 1996 Direct demonstration of small intestinal secretion and site-dependent absorption of the beta-blocker talinolol in humans. Clin Pharmacol Ther 59: 541-549
15. Greiner B, Eichelbaum M, Fritz P, Kreichganer H-P. von Richter O, Zundler J, Kroemer HK 1999 The interaction of digoxin and rifampin: role of intestinal P-glycoprotein. J Clin Invest 104: 147-153
16. Hager WD, Fenster P, Mayersohn M, Perrier D, Graves P, Marcus FI, Goldman S 1979 Digoxin-quinidine interaction. Pharmacokinetic evaluation. N Engl J Med 300: 1238-1241
17. Holtbecker N, Fromm MF, Kroemer HK, Ohnhaus EE, Heidemann H 1996 The nifedipine-rifampin interaction. Evidence for induction of gut wall metabolism. Drug Metab Dispos 24: 1121-1123
18. Karlsson J, Kuo SM, Ziemniak J, Artursson P 1993 Transport of celiprolol across human intestinal epithelial (Caco-2) cells: mediation of secretion by multiple transporters including P-glycoprotein. Br J Pharmacol 110: 1009-1016
19. Kim RB, Fromm MF, Wandel C, Leake B, Wood AJJ, Roden DM, Wilkinson GR 1998 The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-I protease inhibitors. J Clin Invest 101: 289-294
20. Kim RB, Wandel C, Leake B. Cvetkovic M, Fromm MF, Dempsey PJ, Roden MM, Belas F, Chaudhary AK, Roden DM, Wood AJJ, Wilkinson GR 1999 Interrelationship between substrates and inhibitors of human CYP3A and P-glykoprotein. Pharm Res 16: 408-414
21. Kivistö KT, Bookjans G, Fromm MF, Griese EU, Münzel P, Kroemer HK 1996 Expression of CYP3A4, CYP3A5 and CYP3A7 in human duodenal tissue. Br J Clin Pharmacol 42: 387-389
22. Kolars JC, Awni WM, Merion RM, Watkins PB 1991 First-pass metabolism of cyclosporin by the gut. Lancet 338: 1488-1490
23. Kolars JC, Schmiedlin-Ren P, Schuetz JD, Fang C, Watkins PB 1992 Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. J Clin Invest 90: 1871-1878
24. Leahey EB Jr, Reiffel JA, Drusin RE, Heissenbuttel RH, Lovejoy WP, Bigger JT Jr 1978 Interaction between quinidine and digoxin. JAMA 240: 533-534
25. Lee CG, Gottesman MM, Cardarelli CO, Ramachandra M, Jeang KT, Ambudkar SV, Pastan I, Dey S 1998 HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry 37: 3594-3601
26. Lennernäs H, Regardh CG 1993 Dose-dependent intestinal absorption and significant intestinal excretion (exsorption) of the beta-blocker pafenolol in the rat. Pharm Res 10:727-731
27. Lown KS, Mayo RR, Leichman AB, Hsiao HL, Turgeon DK, Schmiedlin R, Brown MB, Guo W, Rossi SJ, Benet LZ, Watkins PB 1997 Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin Pharmacol Ther 62: 248-260
28. Mayer U, Wagenaar E, Beijnen JH, Smit JW, Meijer DK, van Asperen J, Borst P. Schinkel AH 1996 Substantial excretion of digoxin via the intestinal mucosa and prevention of long-term digoxin accumulation in the brain by the mdr1 a P-glycoprotein. Br J Pharmacol 119: 1038-1044
29. Mayer U, Wagenaar E, Dorobek B, Beijnen JH, Borst P, Schinkel AH 1997 Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833. J Clin Invest 100: 2430-2436
30. Pedersen KE, Christiansen BD, Klitgaard NA, Nielsen-Kudsk F 1983 Effect of quinidine on digoxin bioavailability. Eur J Clin Pharmacol 24: 41-47
31. Riddell JG, Shanks RG, Brogden RN 1998 Celiprolol. A preliminary review of its pharmacodynamic properties and its therapeutic use in hypertension and angina pectoris. Drugs 34: 438-458
32. Schinkel AH 1997 The physiological function of drug-transporting P-glycoproteins. Semin Cancer Biol 8: 161-170
33. Schinkel AH, Smit JJ, van Tellingen O, Beijnen JH, Wagenaar E, van Deemter L, Mol CA, van der Valk MA, Robanus-Maandag EC, te Riele HP, Berns AJM, Borst P 1994 Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77:491-502
34. Schinkel AH, Wagenaar E, Mol CA, van Deemter L 1996 P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 97: 2517-2524
35. Schinkel AH, Wagenaar E, van Deemter L, Mol CA, Borst P 1995 Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J Clin Invest 96: 1698-1705
36. Schuetz EG, Beck WT, Schuetz JD 1996 Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Mol Pharmacol 49: 311-318
37. Schuetz EG, Yasuda K, Arimori K, Schuetz JD 1998 Human MDR1 and mouse mdr1 a P-glycoprotein alter the cellular retention and disposition of erythromycin, but not of retinoic acid or benzo(a)pyrene. Arch Biochem Biophys 350: 340-347
38. Spahn-Langguth H, Baktir G, Radschuweit A, Okyar A, Terhaag B, Ader, Hanafy A, Langguth P 1998 P-glycoprotein transporters and the gastrointestinal tract: evaluation of the potential in vivo relevance of in vitro data employing talinolol as model compound. Int J Clin Pharmacol Ther 36: 16-24
39. Sparreboom A, van Asperen J, Mayer U, Schinkel AH, Smit JW, Meijer, DK, Borst P, Nooijen WJ, Beijnen JH, van Tellingen O 1997 Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci USA 94: 2031-2035
40. Tanigawara Y, Okamura N, Hirai M, Yasuhara M, Ueda K, Kioka N, Komano T, Hori R 1992 Transport of digoxin by human P-glycoprotein expressed in a porcine kidney epithelial cell line (LLC-PK1). J Pharmacol Exp Ther 263: 840-845
41. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham, MC 1987 Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 84: 7735-7738
42. Thummel KE, O 'Shea D, Paine MF, Shen DD, Kunze KL, Perkins JD, Wilkinson GR 1996 Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin Pharmacol Ther 59: 491-502
43. Watkins PB 1997 The barrier function of CYP3A4 and P-glycoprotein in the small bowel. Adv Drug Del Rev 27: 161-170
44. Watkins PB, Brighton SA, Schuetz EG, Molowa DT, Guzelian PS 1987 Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man. J Clin Invest 80: 1029-1036